Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XRAY VISION: xevinapant plus radiotherapy versus placebo plus radiotherapy in high-risk resected locally advanced SCCHN patients ineligible for cisplatin
NL-OMON60434Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Xevinapant + radiotherapy with Placebo + radiotherapy (2 arms). Primary endpoint: Disease-Free Survival. Started Apr 2023; status: completed.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON60434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60434.